SynthesisIrish journal of medical science2026
Is radiofrequency ablation of renal cancer metastases a suitable alternative to surgical metastectomy: A systematic review.
Synthesis in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spontaneously ruptured breast metastasis from renal cell carcinoma 20 years post-nephrectomy: a case report and literature review.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPercutaneous ablative procedures such as radiofrequency ablation (RFA) are recognised as safe and effective treatment for small renal masses. These techniques are routinely used for metastases of other cancers such as lung or colorectal cancer.
aimsWe aim to assess the feasibillity and safety of these treatments for metastatic RCC.
methodsA systematic review of the literature was performed searching for primary papers reporting outcomes on percutaneous ablative procedures such as RFA or cryoablation for the treatment of metastases of RCC. The study is registered with PROSPERO and is conducted in line with PRISMA guidelines.
resultsSeven studies were identified with a total of 752 patients undergoing 961 radiofrequency ablation sessions for 1423 metastases were included in this systematic review. Of the seven studies, 4 were single centre retrospective cohort studies, 2 were multi-centre retrospective cohort studies and 1 was monocentric prospective study. The mean age of patients in this study is 63.74 years and 34.4% were female. Mean follow up ranged from 10 to 61 months. Mean tumour size ranged from 12 to 79 mm. Overall Survival ranges from 50 to 100% from 5 years onwards post RFA. Overall we report a 30% risk of pneumothorax, 1.2% risk of non-pneumothorax complication and 0.1% risk of death per metastases treated.
conclusionThis is the first systematic review on this subject. We have shown that RFA can be safely used for metastatic RCC. It demonstrates acceptable oncological outcomes, comparable to surgical metastectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.